The compounded GLP-1 market has grown dramatically since 2023, and with that growth has come a range of quality — from exceptional, accredited operations to providers that cut corners in ways that put patients at risk. Knowing what to look for can protect you from the worst operators and help you find the best ones.
Here are nine warning signs that should give you pause before committing to a compounded GLP-1 program.
1. They Won't Tell You Which Pharmacy Compounds Your Medication
This is the biggest red flag of all. Every legitimate compounded GLP-1 program uses a specific compounding pharmacy — and they should have no problem telling you which one. If your provider deflects, claims proprietary information, or simply can't answer the question, that opacity should concern you.
Why it matters: pharmacy identification allows you to independently verify licensing, check inspection histories, confirm LegitScript certification, and research any FDA warning letters or state board actions. A provider that keeps this information hidden may be doing so because the pharmacy wouldn't survive your scrutiny.
2. Pricing That's Too Good to Be True
Compounded semaglutide has real costs: pharmaceutical-grade API, cleanroom compounding by trained personnel, quality testing, cold-chain shipping, and medical oversight. The current market range for reputable programs is approximately $99–$350 per month, depending on medication, dose, and included services.
A program offering compounded semaglutide at $40–$50 per month should raise immediate questions about where the savings come from. Common cost-cutting measures include using research-grade rather than pharmaceutical-grade API, skipping potency or sterility testing, operating without proper cleanroom infrastructure, and eliminating meaningful medical oversight.
Low prices aren't automatically dangerous, but they warrant extra due diligence. Ask specifically about API sourcing, testing protocols, and pharmacy accreditations before assuming a rock-bottom price is simply a better deal.
3. No Medical Consultation Before Prescribing
GLP-1 medications are prescription drugs with real contraindications, potential side effects, and drug interactions. Any program that ships medication without a meaningful medical evaluation — including health history review, contraindication screening, and BMI/eligibility assessment — is not practicing responsible medicine.
"Meaningful" doesn't necessarily mean a 30-minute video call. Asynchronous consultations (questionnaire-based assessments reviewed by a licensed prescriber) can be clinically appropriate when they're thorough. But a one-page form with no follow-up questions, no medical history review, and instant approval is not a consultation — it's a checkout page.
4. No Follow-Up or Monitoring Plan
GLP-1 treatment isn't a one-time prescription. It requires ongoing monitoring for side effects, dose adjustments based on response and tolerability, and periodic health assessments. Programs that prescribe and disappear — no scheduled check-ins, no side effect monitoring, no dose adjustment consultations — are prioritizing transaction volume over patient safety.
Quality programs include structured follow-up at key milestones: after the first dose, during titration, at target dose achievement, and periodically during maintenance. If your provider's involvement ends the moment your credit card is charged, that's a red flag.
5. Pressure Tactics and Urgency-Based Marketing
Legitimate medical providers don't create false urgency. Watch for language like:
"Supply is running out — order now before it's too late!"
"Special pricing expires today!"
"Only 3 spots left this month!"
These are sales tactics, not medical communications. Responsible providers communicate factual information about availability and pricing without manufactured pressure. If a provider's marketing feels more like a countdown timer than a medical practice, your skepticism is warranted.
6. No LegitScript Certification or Verifiable Credentials
LegitScript certification is the industry standard for verifying online pharmacy and telehealth legitimacy. While not every legitimate pharmacy has LegitScript certification (it's voluntary), the absence of any independently verifiable credentials — no LegitScript, no PCAB accreditation, no verifiable state licensing — is concerning.
At minimum, you should be able to verify the pharmacy's active state license through the relevant Board of Pharmacy website. If you can't independently confirm that the pharmacy is legally licensed to operate, don't use them.
7. No Certificates of Analysis Available
A Certificate of Analysis (COA) documents the quality testing results for a specific batch of medication — potency, purity, sterility, and endotoxin levels. Quality pharmacies generate COAs for every batch and can provide them to patients upon request.
A pharmacy that can't or won't provide COAs may not be testing their products at the level patients deserve. While some patients never ask for COAs, the pharmacy's willingness to provide them is a signal of their confidence in their product quality.
8. Recent FDA Warning Letters Citing Product Quality Issues
FDA warning letters are public documents. Before committing to a provider, check whether their compounding pharmacy has received any recent warning letters — particularly ones citing sterility failures, potency issues, or contamination findings.
A warning letter doesn't automatically mean current products are unsafe — pharmacies can and do correct deficiencies. But a pattern of repeat violations, or a very recent warning letter without demonstrated corrective action, is a legitimate concern. You can search the FDA's warning letter database at fda.gov.
9. They Claim Their Compounded Product Is "FDA-Approved" or "Equivalent to Wegovy"
Compounded medications are not FDA-approved. Period. A provider that claims their compounded semaglutide is "FDA-approved," "equivalent to Wegovy," or "the same as the brand-name product" is making false claims that violate federal law.
Compounded semaglutide uses the same active ingredient as Wegovy, but it is not the same product. It hasn't undergone the FDA approval process, hasn't been tested in the clinical trials that established Wegovy's safety and efficacy profile, and isn't manufactured under the same conditions. Honest providers are transparent about this distinction.
What Good Providers Say Instead
"Our compounded semaglutide contains the same active pharmaceutical ingredient as Wegovy but is prepared by a licensed compounding pharmacy and is not FDA-approved." This kind of clear, honest framing is the standard you should expect.
The Flip Side: Green Flags
For every red flag, there's a corresponding green flag that signals quality:
They name their pharmacy partner and encourage you to verify credentials. They price competitively but not suspiciously low. They require a genuine medical evaluation. They provide structured follow-up and monitoring. They communicate factually without pressure tactics. They hold LegitScript certification and/or PCAB accreditation. They offer COAs upon request. They have a clean regulatory history. They're honest about compounding limitations.
The compounded GLP-1 market has plenty of excellent providers operating at high standards. These red flags aren't meant to scare you away from compounded medications — they're designed to help you find the providers that deserve your trust.